18 Biological activity of a combination of fulvestrant 500 mg (F500) plus anastrozole versus F500 alone or anastrozole alone as neoadjuvant treatment for breast cancer

J.F.R.Robertson; J.M.Dixon; D.M.Sibbering; A.Jahan; I.O.Ellis; E.Channon; R.I.Nicholson; J.M.W.Gee

首页> 外文期刊>European Journal of Cancer Supplements >18 Biological activity of a combination of fulvestrant 500 mg (F500) plus anastrozole versus F500 alone or anastrozole alone as neoadjuvant treatment for breast cancer

【24h】

18 Biological activity of a combination of fulvestrant 500 mg (F500) plus anastrozole versus F500 alone or anastrozole alone as neoadjuvant treatment for breast cancer

机译：18氟维司群500 mg（F500）加阿那曲唑与单独F500或单独阿那曲唑组合作为乳腺癌新辅助治疗的生物学活性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第3期|共1页
作者
J.F.R.Robertson; J.M.Dixon; D.M.Sibbering; A.Jahan; I.O.Ellis; E.Channon; R.I.Nicholson; J.M.W.Gee;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer [J] . John FR Robertson, J Michael Dixon, D Mark Sibbering, Breast Cancer Research . 2013,第2期

机译：一项随机试验评估短期（手术前）氟维司群500 mg加阿那曲唑相对于单独氟维司群500 mg或单独使用阿那曲唑对原发性乳腺癌的生物学活性
2. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. [J] . Robertson JF, Llombart Cussac A, Rolski J, Journal of Clinical Oncology . 2009,第27期

机译：氟维司群500毫克对阿那曲唑1毫克作为晚期乳腺癌的一线治疗的活性：FIRST研究的结果。
3. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study [J] . Ellis Matthew J., Llombart-Cussac Antonio, Feltl David, Journal of Clinical Oncology . 2015,第32期

机译：晚期乳腺癌的一线治疗中的夫伐敏特500 mg与阿那曲唑1 mg对比：II期FIRST研究的总体生存率分析
4. Preliminary Experiences of DBT (digital breast tomosynthesis) and Hybrid 18F-FDG-PET/MR (PETMR) for Neoadjuvant Chemotherapy (NAC) Cases in Breast Cancer [C] . Nachiko Uchiyama MD, Hiroaki Kurihara MD, Takayuki Kinoshita MD, International Workshop on Breast Imaging . 2018

机译：DBT（数字乳腺断层合成）和混合18F-FDG-PET / MR（PETMR）在乳腺癌新辅助化疗（NAC）病例中的初步经验
5. Pharmacokinetics of Metformin and Graviola Leaves Extract (Annona Muricata L.) Using Hplc and Their Biological Activity in Combination on Breast Cancer Cell Lines [D] . Hashem, Saba Aws. 2021

机译：二甲双胍和Graviola的药代动力学使用HPLC及其生物活性在乳腺癌细胞系中留下提取物（Annona Muricata L.）
6. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer [O] . John FR Robertson, J Michael Dixon, D Mark Sibbering, 2013

机译：一项随机试验评估短期（手术前）氟维司群500 mg加阿那曲唑相对于单独氟维司群500 mg或单独使用阿那曲唑对原发性乳腺癌的生物学活性
7. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer [O] . John FR Robertson, J Michael Dixon, D Mark Sibbering, 2013

机译：一项随机试验评估短期（手术前）氟维司群500 mg加阿那曲唑相对于单独氟维司群500 mg或单独使用阿那曲唑对原发性乳腺癌的生物学活性

18 Biological activity of a combination of fulvestrant 500 mg (F500) plus anastrozole versus F500 alone or anastrozole alone as neoadjuvant treatment for breast cancer

著录项

相似文献

相关主题

期刊订阅